{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:25:55Z","timestamp":1768674355529,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.dld.2008.08.009","type":"journal-article","created":{"date-parts":[[2008,10,20]],"date-time":"2008-10-20T08:26:01Z","timestamp":1224491161000},"page":"303-307","source":"Crossref","is-referenced-by-count":30,"title":["Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone\/buprenorphine maintenance therapy"],"prefix":"10.1016","volume":"41","author":[{"given":"B.","family":"Belfiori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ciliegi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chiodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bacosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2008.08.009_bib1","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1086\/427475","article-title":"Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment","volume":"40","author":"Backmund","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2008.08.009_bib2","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","article-title":"Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users","volume":"40","author":"Edling","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2008.08.009_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1440-1746.2002.02730.x","article-title":"Is severe liver disease a common outcome for people with chronic hepatitis C?","volume":"17","author":"Dore","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2008.08.009_bib4","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seef","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2008.08.009_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jurban\/jth114","article-title":"Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck depression inventory","volume":"81","author":"Golub","year":"2004","journal-title":"J Urban Health"},{"key":"10.1016\/j.dld.2008.08.009_bib6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.dld.2008.08.009_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2008.08.009_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in metadone maintenance patients: an interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.dld.2008.08.009_bib9","first-page":"81","article-title":"Metadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use","volume":"68","author":"Verrando","year":"2005","journal-title":"Gastroenterol Belg"},{"key":"10.1016\/j.dld.2008.08.009_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hep.1840360703","article-title":"Consensus Development Conference Statement. Management of Hepatitis C","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2008.08.009_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"AASLD practice guideline: diagnosis, management and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2008.08.009_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alpha 2b-plus ribavirin compared with interferon alpha 2b-plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2008.08.009_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of Interferon-based therapy of chronic hepatitis C in patients on metadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2008.08.009_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1360-0443.2006.01698.x","article-title":"Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes","volume":"102","author":"Guadagnino","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.dld.2008.08.009_bib15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2008.08.009_bib16","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (E.M.C.D.D.A.), <http:\/\/ar2006.emcdda.europa.eu\/it\/page011-it.html>; 2006 [accessed 25.06.07]."},{"key":"10.1016\/j.dld.2008.08.009_bib17","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (E.M.C.D.D.A.), <http:\/\/stats06.emcdda.europa.eu\/en\/elements\/inffig06d-en.html>; 2006 [accessed 25.06.07]."},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2008.08.009_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042560-199802001-00004","article-title":"Prevalence and incidence of hepatitis C virus infection among young adult injection drug users","volume":"18","author":"Garfein","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.dld.2008.08.009_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2004.05.012","article-title":"Peginterferon alpha 2-b plus ribavirin for na\u00efve patients with genotype 1 chronic hepatitis C: a randomized controlled trial","volume":"41","author":"Bruno","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2008.08.009_bib20","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1001\/jama.285.18.2355","article-title":"Regular outpatient medical and drug abuse care and subsequent hospitalization of person who use illicit drugs","volume":"285","author":"Laine","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dld.2008.08.009_bib21","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.286.14.1715","article-title":"Integrating primary medical care with addiction treatment: a randomized controlled trial","volume":"286","author":"Weisner","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dld.2008.08.009_bib22","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1086\/427447","article-title":"Treating hepatitis C virus infection in active substance users","volume":"40","author":"Sylvestre","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2008.08.009_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865808006348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865808006348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T00:28:06Z","timestamp":1545697686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865808006348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1590865808006348"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2008.08.009","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}